c7Ado) (6, 11) ; they are particularly active against (-)RNA strand viruses (i.e., measles, parainfluenza, and vesicular stomatitis), double-stranded (±)RNA viruses (i.e., reo), and poxviruses (i.e., vaccinia). In particular, C-c3Ado offers promise as a broad-spectrum antiviral agent, since it inhibits the replication of vesicular stomatitis, measles, parainfluenza, vaccinia, and reovirus at a concentration of 0.2 to 1 ,ug/ml but is not toxic for the host cells at a concentration of 400 ,ug/ml (11) .
A common biochemical characteristic of (S)-DHPA (18, 22) , D-eritadenine (18) , c3Ado (1, 14) , C-Ado (5, 14) , and C-c3Ado (19) is that they all are potent inhibitors of Sadenosyl-L-homocysteine (AdoHcy) hydrolase, with Ki values ranging from 1 nM to 4 ,iM, depending on the compound and the assay system, e.g., nature and purity of the enzyme. AdoHcy hydrolase catalyzes the reversible hydrolysis of AdoHcy to adenosine and homocysteine. Inhibition of AdoHcy hydrolase results in the accumulation of AdoHcy, which is both the product and a feedback inhibitor of S-adenosylmethionine-dependent methylation reactions. Such methylation reactions are required for the 5'-capping of viral mRNAs, and therefore, inhibitors of AdoHcy hydrolase may be expected to inhibit the maturation of viral mRNAs and the production of progeny virus particles.
Recently, a novel class of carbocyclic analogs of purine nucleosides has been decribed in which the ribose moiety is replaced by a cyclopentene ring (15, 16, 21, 23, 24) . These compounds were originally isolated from the culture broth of an actinomycete, Ampullarilla regularis A11079, and designated neplanocins. Neplanocins A, B, and C have antitumor activities in mice, with neplanocin A being more potent than the established antitumor drugs arabinosylcytosine, 5- fluorouracil, cyclophosphamide, 6-mercaptopurine, daunorubicin, doxorubicin, and mitomycin C in increasing the life span of mice inoculated with murine leukemia L1210 cells (21) .
The prototype of the neplanocins, neplanocin A ((-)-9-[trans-2,trans-3-dihydroxy-4-(hydroxymethyl)cyclopent- 4- enyl]adenine) has recently been described as a potent inhibitor of AdoHcy hydrolase with a Ki of 8.39 nM for the purified bovine liver enzyme (3) . Neplanocin A was also found to inhibit vaccinia virus replication in murine L-929 cells at a concentration of 0.5 to 1.0 ,uM (3) . In view of the striking parallelism between the antiviral activity of adenosine analogs and their inhibitory effects on AdoHcy hydrolase, it seemed imperative to further explore neplanocin A and its derivatives for their broad-spectrum antiviral properties.
MATERIALS AND METHODS
Test compounds. The neplanocins (neplanocin A, neplanocin C, neplanocin D, ara-neplanocin A, and 2'-deoxyneplanocin A) were obtained from Toyo Jozo Co., ShizuokaKen, Japan. The structural formulae of the compounds are depicted in Fig. 1 (Table 2) . Again, neplanocins A and C turned out to be efficient inhibitors of these viruses; the potency of neplanocin C was comparable to that of C-c3Ado, whereas neplanocin A was at an average fivefold more potent. Neplanocin A by far exceeded ribavirin and (S)-DHPA in potency against any of the viruses assayed in Vero cells. As compared with ribavirin, (S)-DHPA, and C-c3Ado, neplanocin A and neplanocin C were also more cytotoxic since they altered normal cell morphology at a concentration of 10 jig/ml, whereas the reference compounds failed to do so at concentrations up to 400 ;ig/ml. Neplanocin D was inhibitory to parainfluenza virus at a concentration of 2 ,ug/ml but was noncytotoxic at 400 pug/ml. Neplanocin A and neplanocin C were less potent antimetabolites for Vero cells ( Ara-neplanocin A >400 >400 150 >400 >100 >100 >100
2'-Deoxy-neplanocin A >400 >400 20 >400 >100 >100 >100
(S)-DHPA >400 >400 150 >400 >100 >100 >100 C-c3Ado >400 >400 0.4 >400 >100 >100 >100 Ribavirin 20 20 10 >400 >100 >100 >100 A and C and C-c3Ado were much more potent than ribavirin. Neplanocins A and C inhibited the replication of vesicular stomatitis virus at concentrations of 0.07 and 0.4 ,ug/ml, respectively; that is 100-or 10-fold lower than their MIC for protein synthesis (6.6 and 3.3 ,ug/ml, respectively). Neplanocin D and 2'-deoxy-neplanocin A were inhibitory to vesicular stomatitis virus at 20 pug/ml but were nontoxic for the host cells at 400 ,ug/ml.
Since vesicular stomatitis virus ranked among the viruses that were most susceptible to the inhibitory effects of the neplanocins, its susceptibility to neplanocins A and C was further examined in a variety of cell lines (Table 4 ). In all cell lines, neplanocin A and neplanocin C inhibited vesicular stomatitis virus replication at a concentration well below their minimal cytotoxic concentration. The ratio of the minimal cytotoxic concentration to the minimal antiviral concentration of neplanocin A ranged from 10 (in CV-1 or BHK 21 cells) to 4,000 (in PRK cells). For neplanocin C the ratio of the minimal cytotoxic to the minimal antiviral concentration fell between 5 
(Vero cells) and 200 (PRK cells).
Based on their potency against vesicular stomatitis virus in cell culture, neplanocins A and C were further investigated for their activity against a lethal vesicular stomatitis virus infection in mice, i.e., newborn mice inoculated subcutaneously with vesicular stomatitis virus and young weaned mice inoculated intranasally with vesicular stomatitis virus. Neplanocins A and C were themselves lethal if administered intraperitoneally at 20 ,ug per mouse to newborn mice or 500 ,ug per mouse to young weaned mice (11 to 13 g). Thus, the doses of neplanocins A and C used in these mice had to be adjusted to maximally 5 ,ug per mouse for the newborn mice and 100 ,ug per mouse for the young weaned mice. In the newborn mice the neplanocins did not offer any protection against vesicular stomatitis virus infection (Table 5 ). Neither did they protect newborn mice against a lethal coxsackievirus type B-4 infection (data not shown). In the young weaned mice, neplanocin A and neplanocin C effected a partial reduction in the mortality rate (Table 5 ), but this reduction was not statistically significant.
DISCUSSION
Neplanocins A and C proved effective against a broad range of viruses, in particular (-)RNA strand viruses (i.e., vesicular stomatitis virus, parainfluenza virus, and measles virus), but they were also effective against (±)RNA viruses (i.e., reovirus) and poxviruses (i.e., vaccinia virus). Other viruses, i.e., herpes simplex virus and the (+)RNA viruses (togavirus and picornavirus) were also affected but to a significantly lesser extent. Thus, the antiviral activity spectrum of neplanocins A and C is remarkably similar to that of the other adenosine analogs (S)-DHPA and C-c3Ado (6) .
As compared with C-c3Ado, neplanocin A was slightly more potent in its antiviral activity but was also more cytotoxic. It achieved an inhibition of vaccinia virus and vesicular stomatitis virus replication at a concentration as low as 0.02 to 0.04 ,ug/ml (Table 1) . Our results thus confirm susceptible to the antiviral activity of neplanocin A, i.e., vaccinia, vesicular stomatitis, parainfluenza, and reovirus, the specificity index (ratio of minimum cytotoxic concentration to minimal antiviral concentration) ranged from 50 to 4,000, depending on the choice of the virus and parameter used to assess cytotoxicity. The specificity index of the reference compound C-c3Ado fell in the range of 500 to 2,000. Neplanocin C was, in general, equally cytotoxic but less potent than neplanocin A. If for each cell system (Tables 1 through 3) , the lowest minimum cytotoxic concentrations were compared to the lowest minimum antiviral concentrations ( with previous findings that hypoxanthine derivatives are, as a rule, less potent antiviral agents than their adenine counterparts, i.e., hypoxanthine arabinoside versus adenine arabinoside (4, 12, 20) , formycin B versus formycin A (13) and 9-(2,3-dihyroxypropyl)hypoxanthine versus 9-(2,3-dihydroxypropyl)adenine (9) .
That the antiviral activity of adenosine analogs may be related to an inhibition of AdoHcy hydrolase was originally postulated for c3Ado (1) and (S)-DHPA (7, 22) . AdoHcy hydrolase has also been proposed as a target for the antiviral action of C-c3Ado (19) , and it also seems to serve as the target for the antiviral activity of the neplanocins. With a Ki of about 0.003 ,ug/ml (3) , it is one of the most potent inhibitors of AdoHcy hdydrolase, and as recently established by De Clercq and Cools (E. De Clercq and M. Cools, Biochem. Biophys. Res. Commun., in press), there appears to be a direct correlation between the antiviral potency of the adenosine analogs and their inhibitory effects on AdoHcy hydrolase.
As demonstrated in Table 4 , the antiviral activity of neplanocins A and C depended to a large extent on the choice of the cell system. The differences in neplanocin susceptibility of a particular virus when assayed in various cell lines, as well as differences in susceptibility of different viruses when tested in the same cell line, may be related to differences in AdoHcy hydrolase activity and concomitant transmethylation reactions under these varying conditions. To unequivocally assess the role of AdoHcy hydrolase as target for the antiviral action of the neplanocins, it would appear necessary to directly measure the AdoHcy activity (or AdoHIcy/S-adenosylmethionine ratio) in virus-infected cells under the same conditions as those used for monitoring the inhibitory effects of the compounds on virus multiplication.
Despite their potent activity in vitro, neplanocins A and C were only weakly effective in vivo. They did not protect newborn mice against a lethal infection with vesicular stomatitis virus, and in young mice inoculated intranasally with vesicular stomatitis virus, they offered only marginal protection. The reasons for the poor performance of neplanocins A and C in vivo remain to be elucidated. Possibly, neplanocins A and C are rapidly deaminated in vivo; neplanocin D, the deaminated product of neplanocin A, is, as shown in Tables 1 through 3 , markedly less potent as an antiviral agent than is neplanocin A.
Neplanocins A and C were lethal for mice at a fairly low dose (20 to 40 mg/kg). These findings, together with the limited antiviral protection afforded by the neplanocins at sublethal doses (Table 5) , cast doubt on the therapeutic potentials of these compounds as antiviral drugs.
